Pierre L. Beaulieu

4.3k citations

79 papers · 2.6k indexed · h-index 32

Co-authors: James Gillard Bruno Haché Dominik Wernic George Kukolj Derrick L. J. Clive Jean‐Simon Duceppe Ginette McKercher Youla S. Tsantrizos
Topics: Hepatitis C virus research (33 papers)HIV/AIDS drug development and treatment (31 papers)Biochemical and Molecular Research (12 papers)
Cited by: Hepatology Organic Chemistry Infectious Diseases
Journals: Nature Journal of the American Chemical Society Journal of Biological Chemistry
Partner nations: Canada Germany Egypt

In The Last Decade

Pierre L. Beaulieu

78 papers receiving 2.4k citations

Peers

Countries citing papers authored by Pierre L. Beaulieu

Since Specialization

Citations

This map shows the geographic impact of Pierre L. Beaulieu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre L. Beaulieu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre L. Beaulieu more than expected).

Fields of papers citing papers by Pierre L. Beaulieu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre L. Beaulieu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre L. Beaulieu. The network helps show where Pierre L. Beaulieu may publish in the future.

Co-authorship network of co-authors of Pierre L. Beaulieu

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre L. Beaulieu. A scholar is included among the top collaborators of Pierre L. Beaulieu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre L. Beaulieu. Pierre L. Beaulieu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity 2015 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu,Gordon T. Bolger,(unknown),Martin Duplessis,Gulrez Fazal,Alexandre Gagnon,Michel Garneau,(unknown),Timothy A. Stammers,George Kukolj,Jianmin Duan	5
2	A prodrug strategy for the oral delivery of a poorly soluble HCV NS5B thumb pocket 1 polymerase inhibitor using self-emulsifying drug delivery systems (SEDDS) 2014 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu,(unknown),Michel Garneau,Laibin Luo,Timothy A. Stammers,(unknown),Dominik Wernic,George Kukolj,Jianmin Duan	13
3	Aza follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 1: Mitigating the genotoxic liability of an aniline metabolite 2014 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu,Gordon T. Bolger,Martin Duplessis,Alexandre Gagnon,Michel Garneau,Timothy A. Stammers,George Kukolj,Jianmin Duan	7
4	Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay 2013 ·Bioorganic & Medicinal Chemistry Letters ·Timothy A. Stammers,René Coulombe,Martin Duplessis,Gulrez Fazal,Alexandre Gagnon,Michel Garneau,Sylvie Goulet,Araz Jakalian,Steven R. LaPlante,Jean Rancourt,Bounkham Thavonekham,Dominik Wernic,George Kukolj,Pierre L. Beaulieu	15
5	Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Timothy A. Stammers,René Coulombe,Jean Rancourt,Bounkham Thavonekham,Gulrez Fazal,Sylvie Goulet,Araz Jakalian,(unknown),Youla S. Tsantrizos,Marc‐André Poupart,Michael Bös,Ginette McKercher,Louise Thauvette,George Kukolj,Pierre L. Beaulieu	19
6	From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: Indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons 2011 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu,James Gillard,(unknown),Jianmin Duan,Michel Garneau,George Kukolj,Marc‐André Poupart	18
7	Indole 5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase with nanomolar potency in cell-based subgenomic replicons (part 2): Central amino acid linker and right-hand-side SAR studies 2011 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu,Catherine Chabot,Jianmin Duan,Michel Garneau,James Gillard,(unknown),Martin Poirier,Marc‐André Poupart,Timothy A. Stammers,George Kukolj,Youla S. Tsantrizos	7
8	Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection. 2010 ·PubMed ·Pierre L. Beaulieu	11
9	N-Acetamideindolecarboxylic acid allosteric ‘finger-loop’ inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies 2010 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu,(unknown),James Gillard,Christian Brochu,René Coulombe,Nathalie Dansereau,Jianmin Duan,Michel Garneau,Araz Jakalian,Peter Kühn,Lisette Lagacé,Steven R. LaPlante,Ginette McKercher,(unknown),Martin Poirier,Marc‐André Poupart,Timothy A. Stammers,Louise Thauvette,Bounkham Thavonekham,George Kukolj	12
10	Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: Improved drug-like properties through C-2 SAR in three sub-series 2010 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu,Nathalie Dansereau,Jianmin Duan,Michel Garneau,James Gillard,Ginette McKercher,Steven R. LaPlante,(unknown),Louise Thauvette,George Kukolj	8
11	Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection 2009 ·Expert Opinion on Therapeutic Patents ·Pierre L. Beaulieu	83
12	Finger loop inhibitors of the HCV NS5B polymerase: discovery and prospects for new HCV therapy. 2006 ·PubMed ·Pierre L. Beaulieu	17
13	Synthesis of (1R,2S)-1-Amino-2-vinylcyclopropanecarboxylic Acid Vinyl-ACCA) Derivatives: Key Intermediates for the Preparation of Inhibitors of the Hepatitis C Virus NS3 Protease 2005 ·The Journal of Organic Chemistry ·Pierre L. Beaulieu,James Gillard,Murray D. Bailey,(unknown),Jean‐Simon Duceppe,Bruno Simoneau,Qiang Wang,Li Zhang,Karl Grozinger,Ioannis N. Houpis,Vittorio Farina,(unknown),(unknown),(unknown)	65
14	Binding Site Characterization and Resistance to a Class of Non-nucleoside Inhibitors of the Hepatitis C Virus NS5B Polymerase 2005 ·Journal of Biological Chemistry ·George Kukolj,Graham A. McGibbon,Ginette McKercher,Martin Marquis,Sylvain Lefèbvre,Louise Thauvette,Jean Gauthier,Sylvie Goulet,Marc‐André Poupart,Pierre L. Beaulieu	100
15	Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. 2004 ·PubMed ·Pierre L. Beaulieu,Youla S. Tsantrizos	42
16	Binding Mode Determination of Benzimidazole Inhibitors of the Hepatitis C Virus RNA Polymerase by a Structure and Dynamics Strategy 2004 ·Angewandte Chemie International Edition ·Steven R. LaPlante,Araz Jakalian,Norman Aubry,Yves Bousquet,Jean‐Marie Ferland,James Gillard,Sylvain Lefèbvre,Martin Poirier,Youla S. Tsantrizos,George Kukolj,Pierre L. Beaulieu	45
17	Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency 2004 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu,Michael Bös,Yves Bousquet,Patrick DeRoy,Gulrez Fazal,Jean Gauthier,James Gillard,Sylvie Goulet,Ginette McKercher,Marc‐André Poupart,(unknown),George Kukolj	74
18	Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives 2003 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu,Michael Bös,Yves Bousquet,Gulrez Fazal,Jean Gauthier,James Gillard,Sylvie Goulet,Steven R. LaPlante,Marc‐André Poupart,Sylvain Lefèbvre,Ginette McKercher,Charles Pellerin,Volkhard Austel,George Kukolj	82
19	Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere 1995 ·Structure ·Liang Tong,Susan Pav,(unknown),Daniel Lamarre,Christiane Yoakim,Pierre L. Beaulieu,Paul C. Anderson	38
20	A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo 1994 ·Nature ·Michel Liuzzi,Robert Déziel,(unknown),Pierre L. Beaulieu,Anne-Marie Bonneau,(unknown),James G. Chafouleas,Michel Garneau,Jorge Jaramillo,Richard L. Krogsrud,Lisette Lagacé,(unknown),(unknown),Yvan Guindon	109

About Pierre L. Beaulieu

Pierre L. Beaulieu is a scholar working on Hepatology, Infectious Diseases and Organic Chemistry, having authored 79 papers that have together received 2.6k indexed citations. Recurring topics across this work include Hepatitis C virus research (33 papers), HIV/AIDS drug development and treatment (31 papers) and Biochemical and Molecular Research (12 papers). The work is most often cited by research in Hepatology (767 citations), Organic Chemistry (1.3k citations) and Infectious Diseases (640 citations). Pierre L. Beaulieu has collaborated with scholars based in Canada, Germany and Egypt. Frequent co-authors include James Gillard, Bruno Haché, Dominik Wernic, George Kukolj, Derrick L. J. Clive, Jean‐Simon Duceppe, Ginette McKercher, Youla S. Tsantrizos, Yves Bousquet and Jean Gauthier. Their work appears in journals such as Nature, Journal of the American Chemical Society and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact